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Abstract 
Group A colicins are proteinaceous bacteriocins encoded by plasmids that exploit the cellular 
envelope protein TolA to translocate the cell wall barrier and cellular envelope of the bacterium 
Escherichia coli. These colicins offer protocols for studying certain protein-protein interactions involved 
in such membrane transport functions. Previous experimentations suggest the carboxyl-terminal domain 
of TolA protein contains specific amino acid binding regions required for the translocation of group A 
colicins into E. coli.  The amino acid sequence of this domain varies between E. coli and other gram-
negative bacterial species.  It has been suggested that this diversity could be utilized to identify specific 
TolA residues involved in the binding of colicins. Additionally, other Enterobacteriaceae species’ TolA 
genes were cloned into a plasmid that is regulated by the monosaccharide sugar, arabinose. This plasmid 
was transformed into an E. coli strain that lacked a functional tolA gene. The plasmid was expressed in 
this strain. Homologous complementation of this phenotype lacking tolA expression has been 
demonstrated through resistance to the bile acid deoxycholate. The expression of this complemented 
phenotype through cloned ΔtolA genes demonstrates expression and translocation of TolA protein through 
the outer membrane into the periplasmic space. Bacterial strains possessing these constructs and 
functional TolA were tested for sensitivity against two group a colicins: A and N. Two such species, 
Chronobacter muytjensii and Yersinia enterocolitica complements the phenotype lacking functional TolA 
with their own encoded TolA proteins. These functional proteins grant sensitivity to various group A 
colicins, apart from colicin N. The TolA proteins of C. muytjensii, E. coli, Y. enterocolitica and the 
corresponding genetic sequences can be contrasted to highlight site of differing residues. These sites of 
genetic sequence divergence in E. coli, C. muytjensii, and Y. enterocolitica can be altered through 
mutagenesis to identify sequence domains required for colicin N binding to TolA, and thus import into 
the corresponding bacterium. 
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Introduction 
 Escherichia coli is one of the most prominently studied and thoroughly understood gram-negative 
bacteria. As a member of the vast Enterobacteriaceae family, E. coli appear bacillus-shaped and 
metabolically function as facultative anaerobes. As such, E. coli primarily survive the synthesis of ATP 
through aerobic respiration when oxygen is available, but may compensate for a lack of oxygen by 
fermenting available sugars to be used in glycolysis. Like other family members, E. coli is able to reduce 
nitrate to nitrite and exercise motility through the usage of flagella. One of the most prominent roles of E. 
coli is its vast types of symbiotic relationship with various higher-level organisms, such as humans, via 
the occupation of their digestive systems. While some E. coli strains have been accepted as commensals 
that prohibit other pathogenic bacteria from colonizing and help facilitate digestion, other strains have 
proven harmful and infections in various clinical settings. It is this significance of these strains that casts 
E. coli and other members of the gram-negative Enterobacteriaceae family, such as the Enterobacter 
genus, into the radars of researchers.   
 As is characteristic of the majority of gram-negative bacteria, E. coli possess a bi-layered 
membrane. The first layer consists of the outer membrane (OM) that exists as the most external 
membrane of the cell, acts as a barrier between cell contents and the environment, and facilitates a point 
of contact for the extracellular space. The second layer is the cytoplasmic membrane (CM) that acts as an 
internal membrane to contain the cell contents and separate them from the OM. An aqueous area 
separates these two membranes using a thin layer of peptidoglycan. This construction is unique to gram-
negative bacteria as gram-positive bacteria do not possess an OM and compensate for this absence with a 
broad peptidoglycan layer. The two membranes differ in their structure to facilitate their unique functions. 
The OM is constituted by glycolipids, such as lipopolysaccharides (LPS) (Silhavy et al., 2010). This 
composition prevents membrane-damaging substances, such as antibiotics or detergents, from entering 
the cell (Nikaido, 2003). The CM is composed of a standard phospholipid bilayer and membranous 
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proteins. The CM is capable of synthesizing energy that facilitates the translocation of molecules through 
the cellular envelope via an ion-electrochemical gradient (Bauman, 2004).  
 Although the OM provides gram-negative bacteria with opportunities for survival not feasible for 
gram-positive bacteria, limitations do exist. One of the primary issues is the OM’s inability to create its 
own energy. This restriction forces the OM, that requires energy for some transport of molecules through 
the membranes, to turn to the CM and the energy from the proton gradient of the proton motive force 
(Postle and Kadner, 2003). However, not all molecules require energy to be translocated. For example, 
hydrophilic molecules are able to enter the cell through porins that consist of beta barrel proteins. These 
molecules must be approximately 600 Daltons or less in order to diffuse. Other porins, such as outer 
membrane protein F (OmpF) and OmpC, exist to facilitate passive diffusion. Of course, not all molecules 
fall within 600 Daltons thus must be transported across the E. coli OM using pores capable of active 
transport. Various protein-systems have evolved to address the need for the OM’s energy demand for 
active transport. Such protein systems occupy the periplasmic space to facilitate an interface between the 
OM and CM and share the CM’s energy with the OM. 
 One such system that exists with various gram-negative bacteria is the Tol system. Although the 
physiological function of this system has not been fully determined, its function can be modeled after the 
TonB system which has been more thoroughly researched. Much of the Tol system has been predicted 
from the perspective of the TonB system. Both protein systems consist of three proteins fixated to the 
CM. ExbB, ExbD, and TonB exist in the TonB system and are paralogous to the TolQ, TolR, and TolA 
proteins of the Tol protein system (Postle and Larsen, 2007). ExbB consists of three segments that span 
the CM and an N-terminus in the periplasmic space that binds to the CM (Kampfenkel and Braun, 1993a). 
ExbB forms a complex with ExbD that utilizes the proton motive force. The TonB protein is also consists 
of three components. The N-terminus domain utilizes the ExbB/ExbD complex to allow TonB to interact 
with the CM (Krewulak and Vogel, 2011, Larsen and Postle, 2001, Lazar, 2014). The second domain fills 
the space between the OM and CM and consists of repeats of proline patterns (Brewer et al., 1990). The 
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final domain, the C-terminus, is ultimately the main point of focus of this project. It is the primary 
effector domain that interacts with OM transporter proteins (Ferguson and Deisenhofer, 2002; Lazar, 
2014). The TonB system utilizes its three proteins to import vitamin B12 and facilitate iron transfer 
through OM active transport (Gresock et al. 2011). This active transport is enabled through energy 
created in the CM by the proton motive force (Postle and Larsen, 2007; Lazar, 2014).  
 One physiological function shared among the TonB and Tol system is their facilitation of colicin 
translocation into the OM and through the CM. Group B colicins have been able to parasitize the TonB 
system and gain cell entry. Complementarily, group A colicins behave similarly with the Tol system. 
However, resistance to these bacteriocins have been obtained through mutations in these genes. The entry 
of colicins into bacteria like E. coli have proven worthy of study due to their unique mechanism of 
entering the cell. Rather than being required to stimulate OM receptors to enter the cell, some mutated 
strains permit colicins to enter cells without having colicins bind to such receptors. Strains permitting this 
receptor-independent translocation of colicins are referred to as tol strains (Webster, 1991). Figure 1 
illustrates both the Tol and TonB systems to offer a side-by-side comparison 
The Tol Protein System 
 As previously stated, much of the understanding that has been gathered about the Tol system has 
been acquired through experiments that predicted its behavior paralleled that of the TonB system. 
Associations between the Tol system and OM stability have been established through various 
experiments. Such studies have exposed cells with mutated Tol systems to pharmaceuticals and detergents 
and transmembrane protein leakage or cell lysis due to a collapsing OM integrity (Lazzaroni et al.,1999; 
Lazar, 2014). As such, dependence of OM stability has been linked to the necessity for a functional Tol 
system. Although such relationships have been supported between these two entities through such 
experimentation, it has been suggested that perhaps another protein or protein system supports the action 
of the Tol system and thus is equally necessary for OM integrity. Pal is one such protein that is believed 
to act as an interface between the CM and OM while forming an energy-consuming complex with the Tol 
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system (Gerding et al., 2007; Lazar, 2014). This complex has recently been identified as a facilitator of 
chemotaxis as it may aid in the maintenance of chemoreceptor polarity (Santos et al., 2014; Lazar, 2014). 
 The Tol proteins are encoded by two operons. The first operon contains the orf1, tolQ, tolR, and 
tolA genes whereas the second operon encodes the tolB, pal, and orf2 genes. Two promoters exist in this 
gene cluster. The first promoter, P1, is believed to promote the transcription of all seven genes mentioned. 
However, the second promoter, PB, only promotes the expression of the final three genes mentioned 
(Vianney, et al., 1996; Lazar, 2014). Further research has found dependence of tolR expression on the 
among of tolQ transcribed (1996). A similar dependence was found between the Ton genes exbD and 
exbB (Ahmer et al., 1995). This relationship that exists in the two paralogous protein systems possibly 
exists to ensure both proteins required to form the ExbB/D or TolQ/R complexes are present (Lazar, 
2014). Orf1 and orf2 are contemporarily known as ybgC and ybgF, respectively. These genes have not 
been demonstrated to be necessary for a functional Tol system (Lazdunski et al., 1998). However, it is 
known that ybgC transcription and translation yields an acyl-coenzyme A thioesterase and ybgF encodes 
a periplasmic protein that may interact with the TolA protein (Zhuang et al., 2002; Sturgis, 2001).   
 The five remaining Tol proteins mentioned are far better understood than YbgC and YbgF. As 
previously mentioned, the TolQ and TolR CM proteins are paralogous to TonB’s ExbB and ExbD 
proteins. It has been demonstrated that TolQ shares 26.3% genetic sequence identity with ExbB, but the 
79.1% of amino acids can be substituted by other amino acids and conserve its function. A similar 
relationship exists between TolR and ExbD with 25% genetic sequence identity being shared (Eick-
Heklmerch and Braun, 1989; Lazar, 2014). The ExbB/D and TolQ/R complexes and their relationship to 
the CM are also comparable. TolQ is an integrated CM protein similar to ExbB while TolR is a 
transmembranous protein similar to ExbD (Kampfenkel and Braun, 1993). The TolQ/R complex has been 
shown to restore partial function to TonB systems lacking ExbB and ExbD (Braun et al., 1996; Brinkman 
and Larsen, 2008; Lazar, 2014).   
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 TolB and Pal proteins do not possess and paralogous relationships to proteins within the TonB 
system. TolB is a periplasmic protein that exists on the peripheral side of the OM and is constituted of an 
N-terminal domain and a C-terminal domain (Bouveret et al., 1995). These two proteins interact in such a 
way that may support OM integrity (Ray et al., 2000). Pal is the only protein of the Tol system that 
directly contacts the OM (Lazar, 2014). This contact is facilitated by the N-terminal of Pal while the C-
terminal is fixated to the thin peptidoglycan layer that exists in the periplasmic space (Lazzaroni and 
Poratlier, 1992). 
  The central protein of this project, the TolA protein of the Tol system, is paralogous to the TonB 
protein of the TonB system (Levengood and Webster, 1989). Both proteins are associated with the CM 
and consist of three domains, each isolated from the others through glycine strings. The first domain of 
TolA anchors the protein to the CM and interacts with TolQ and TolR (Journet et al., 1999). It is believed 
that the creation of the electrochemical gradient and proton motive force (pmf) of the CM are aided by a 
complex formed between TolQ, A and R (Germon et al., 2001). Domain I is highly conserved in all E. 
coli strains (Lazar, 2014). The second domain of TolA is separated contains high concentrations of 
alanine, lysine, and glutamic acids (Lazar, 2014). This domain is believed to provide a tangible link 
between the OM and CM through the periplasm.  
 The third domain of TolA is the most pertinent TolA domain to this project. Domain III is 
believed to form complexes with various porins such as OM proteins C and F that other domains are 
unable to facilitate (Derousiche et al., 1996). The genetic sequence of Domain III is also highly conserved 
among all E. coli strains. The C-terminal of TolA interacts with TolB to facilitate interactions between the 
other protein components of the CM and OM as well as between Pal and the OM (Walburger et al., 
2002). The TolA-Pal interactions are powered by the pmf (Cascales et al., 2002). It is ultimately the C-
terminal of this domain that facilitates colicin import via interactions with the colicin N-terminal.  
 Both colicins and bacteriophage are able to parasitize the Tol system to enter target cells. A 
protein synthesized by viral Ff bacteriophage genes has been shown to interact with Domain III of TolA 
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to initiate infection (Riechmann and Holliger, 1997). Similar interactions have been shown between the 
TonB system and T1 phages (Hantke and Braun, 1978). However, in terms of colicins, only certain 
classifications of colicins can exploit either protein system. Group A colicins require the Tol system for 
translocation across the cellular envelope, but group B colicins utilize the TonB system (Davies and 
Reeves, 1975a, b).  
Colicin Bacteriocins 
 Some Escherichia coli strains are capable of synthesizing and secreting toxins that eliminate 
bacteria with close genetic similarity. These toxins, more specifically known as colicins, are encoded by 
plasmids and may be an offensive mechanism to eliminate nearby bacterial competition. Various colicins 
have been identified from other bacterial species (Lazar, 2014). Colicins have been classified as either 
group A or B, depending on which protein system they parasitize to enter the cell (Davies and Reeves, 
1975a, b).  In addition to plasmids encoding the colicin itself, a protein capable of preventing the colicin-
synthesizing cell from being harmed by the colicin is also encoded (Jacob et al., 1952). This protective 
protein is known as the immunity protein and is encoded by the same plasmid that encodes the colicin 
(Jacob et al., 1952). This supports the notion of colicins being a competitive survival advantage since 
progeny must receive the plasmid in order to confer colicin immunity and retain offensive colicin 
production.  
 All colicins are composed of three domains: The N-terminal domain, the central domain, and the 
C-terminal domain. Each domain possesses its own unique function. Colicin translocation is initiated by 
the central domain binding to the appropriate receptor on the OM of the target cell (Brunden et al., 1984; 
Lazar, 2014). The stimulated receptor depends on which colicin is attempting import into the cell. Table I 
details which proteins and receptors are required for translocation of which colicins.  Once the colicin’s 
central domain has bound to the OM receptor, the N-terminal aids in translocation of the colicin to the 
CM and its passing through the OM and periplasm (Benedetii et al., 1991). For group A colicins, 
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translocation cannot occur without TolA, thus provides the basis for this project (Benedetii et al., 1991). 
The C-terminal domain is ultimately responsible for cytotoxicity (Lazar, 2014).  
 Colicins can exercise cytotoxicity through several techniques that are specific to different targets. 
One such mechanism is through compromising the synthesis of peptidoglycan. The group B colicin, 
colicin M, accomplishes this through preventing peptidoglycan subunits from polymerization (Ghachi et 
al., 2006).  Other colicins, such as the group A E2 and E3 colicins, function by acting as endonucleases 
and inhibiting protein synthesis by degrading DNA or RNA (Housden et al., 2005). Another common 
mechanism for practicing colicin cytotoxicity is the perforation the CM, ultimately creating pores 
(Hilsenbeck et al., 2004). These pores alter CM homeostasis and disturb the cell ion gradients that allow 
the cell to utilize the proton motive force in a phenomenon known as uncoupling (Hilsenbeck et al., 
2004).  
The Relationship Between the Tol Protein System and Colicin Translocation 
 Before group A colicins can completely enter the target cell, they must pass through the OM into 
the periplasmic space. In this area between the two membranes, the colicin will encounter the Tol 
proteins. In order for the group A colicins to enter the periplasmic space, they must first stimulate the OM 
proteins and receptor proteins, then be transported through the OM by OmpF or TolC porins (Houdsen et 
al., 2005). Colicin N is an exception to this process as it only requires OmpF to enter the periplasmic 
space and forgoes the need for receptor proteins or other OM proteins (Baboolal et al., 2008). Upon 
colicin binding to an OM receptor, an unfolding of the colicin protein occurs to facilitate its translocation 
through the OM (Baboolal et al., 2008). The N-terminus of the colicin further progresses translocation 
through its communication with TolB as it passes through an OmpF porin (Loftus et al., 2006).  The 
region of the colicin’s N-terminal responsible for binding TolB is referred to as the “TolB box” (Lazar, 
2014).  
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 Once the N-terminal of the colicin has been bound to TolB, the colicin binds TolA at a site 
distinct from that of TolB. The colicin binding site that interacts with this third domain of colicin A, 
known as the “TolA box” is believed to be located between residues 52-97 of colicin N (Li et al., 2012). 
Once the colicin is bound to TolA, it releases TolB then binds to TolR. The same residues used to bind 
TolB are used to bind TolR, thus TolB must be released before TolR can be bound by the colicin (Journet 
et al., 2011). The exact interactions that exist between TolQ and colicins are largely undefined to date.  
 The mechanism by which energy is supplied to proteins within the Tol system during colicin 
import seems to vary depending on the colicin in question. Like the TonB system, it the Tol system may 
uses an electrochemical ion gradient within the CM to power colicin translocation (Braun et al., 1980). 
However, colicin A, a group A colicin, has proven to successfully translocate without the use of such a 
gradient. Colicin A utilizes voltage-dependent potassium efflux channels to contact the CM (Bourdineaud 
et al., 1990). A lag time exists between colicin A contacting the CM and efflux which suggests that the 
uptake of colicin A is energy independent (Lazar, 2014). It is possible that other group A colicins may 
obtain an interface with the CM in similar energy-independent ways after initiating import through the 
Tol system.  
 This project aims to identify specific sites in the domain III of the TolA protein that facilitate 
colicin N binding and interactions. Such ideas expand upon the previous works of Weitzel and Larsen 
(2008), Zook (2012), and Lazar (2014) and adopt a similar approach that focuses on understanding 
TolA/colicin N interactions from an evolutionary perspective. Once it was determined that Yersinia 
enterocolitica TolA could function within the tolA 1038 E. coli strain  in terms of conferring colicin A 
sensitivity and OM integrity, additional colicins were tested (Weitzel and Larsen, 2008). Eventually, it 
was determined that sensitivity to colicin N was not conferred in this system due to the lack of the 
appropriate colicin binding region domain III of the E. coli TolA C-terminal (2008). This binding domain 
was posited to be in the final 85 residues of domain III of the E. coli C-terminal TolA. These results are 
cohesive with the recent identification of a residue segment of domain III (residues 44-66) that has proven 
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to be crucial for colicin N activity and mimic the residue of G3P bacteriophage (Gokce et al., 2000; 
Lazar, 2014). 
 This research was further expanded to include Chronobacter species into the ΔtolA 1038 bacteria 
(Zook, 2012; Lazar, 2014). Such experimentation determined that the C. muytjensii strain was able to 
facilitate OM integrity in the 1038 strain just as Weitzel and Larsen had done with Y. enterocolitica TolA. 
in the tolA 1038 E. coli strain. Such results warranted further study using this evolutionary-derived 
strategy to examine genetically divergent tolA genes in different species and restore group A colicin 
sensitivities (Lazar, 2014). Such previous studies revealed only partial sensitivity to colicin N in C. 
muytjensii and Y. enterocolitica thus questions remained regarding role of the C-terminus of domain III 
TolA in group A colicin binding.  
Hypothesis and Research Questions 
 This purpose of this project is to expand upon these related studies in terms of identifying specific 
colicin N binding sites within TolA residues that are required for colicin N translocation (Lazar, 2014). 
Sensitivity assays of colicins A and N were executed through spot titers (Larsen et al., 2001). The wild-
type E. coli, tolA E .coli, and C. muytjensii clones from Zook were researched in this study. The Y. 
enterocolitica clones from Weitzel and Larsen were used as well. Previous work by Gertz (2016) 
provided data and models for C. muytjensii mutants that lacked a terminal Q on the C-terminus. 
Ultimately, this project’s aim is to identify a colicin N binding site within domain III of TolA from E. 
coli, C. muytjensii, and Y. enterocolitica using site-directed mutagenesis of this region and spot titer 
assays to measure colicin sensitivity.   
 
Materials and Methods 
Media 
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Bacterial strains were cultured in Luria-Bertani (LB) broth and on Luria-Bertani agar (LBA) plates 
(Lazar, 2014). Colicin sensitivity spot titers were executed by mixing bacterial strains in liquid cultures 
with liquid tryptone agar (0.75% w/v agar; “T-top”). This mixture was spread onto tryptone agar plates 
(1.5% w/v agar; “T-plates”; Lazar, 2014). Both broth and solid media were laced with 100 μg mL-1 
ampicillin and ʟ-arabinose when specified. 
Bacterial Strains 
 Each bacterial strain presented in this project is summarized in Table II of the appendix. The 
wild-type strain utilized was the Escherichia coli (E. coli) K12 strain W3110 (Hill and Harnish, 1981). 
The tolA strain used, RA1038, was a W3110 derivative engineered by Weitzel and Larsen (2008). The 
bacterial strains used to produce the colicin stock solutions were derived from E. coli K12 strains 
BZB2191 and BZB2123 for colicins A and N respectively. These strains carry the plasmid that encode for 
these colicin. These cells were provided by Dr. Anthony Pugsley (Institut Pasteur; Paris, France). Another 
K12 E. coli derived strain, NEB5-, was used to observe the recombinant plasmids constructed for this 
project. These cells were acquired from New England Biolabs (Ipswich, MA). Plasmids containing 
functional tolA genes from Chronobacter muytjensii (C. muytjensii) and Yersinia enterocolitica (Y. 
enterocolitica) also used in this project. Both strains were originally obtained from the American Type 
Culture Collection as ATCC51329 and ATCC23715 respectively. 
Colicin Stock Solutions 
 The colicin stock solutions of colicins A and N were previously synthesized by Lazar (2014). 
These were obtained from bacterial strains that contained the appropriate plasmid to encode for each 
colicin respectively. The E. coli K12 strains BZB2101 and BZB2123 contained the plasmids that encoded 
for colicins A and N and respectively (Lazar 2014). These strains were provided by Dr. Anthony Pugsley 
(Institut Pasteur; Paris, France).  The E. coli K12 strains BZB2101 and BZB2123 were cultured overnight 
in 5mL LB. The following day, 2.5mL aliquots of each respective overnight culture was added to 50 mL 
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of LB, respectively. This mixture was grown at 37 C with shaking until absorbance at 550 nanometer 
wavelength was equal to 1.0. Absorbance was measured in a Spectronic 20 spectrophotometer with a path 
length of 1.5 cm. Once an absorbance of 1.0 was achieved, 25 µl of mitomycin C (1mg/ml) was added to 
cause colicin production. The cells were incubated at 37 C for four more hours, then harvested with a 10 
minutes centrifugation at 6,000 rpm at 4C. The supernatant was then discarded from each sample and the 
pellets were suspended in 5mL of 1X M9 salts. The resuspensions were transferred to a new tube. The 
cells were lysed using sonication and then filtered through a sterile 0.45 μm filter. The product was stored 
at -20C. Serial five-fold dilutions were prepared using LB as the solvent.  
Plasmid Constructs 
 Table III itemizes each of the plasmids utilized and researched in this project. In order to identify 
homologous complementation or DNA sequence overlap among the various TolA proteins studied within 
E. coli, plasmids containing these genes had to be made (Lazar 2014). The plasmid pBAD24, whose 
expression is regulated by the monosaccharide arabinose, facilitated this matter (Guzman et al., 1995; 
Lazar, 2014). This plasmid encodes ampicillin resistance to aid in mutant screening. Transforming this 
cell into the 1038 tolA to act as negative control during spot titer phenotyping. A positive control, 
previously constructed by Weitzel and Larsen (2008), was employed. This plasmid, known as pRA004, 
encoded the E. coli TolA protein.  
The pBAD24-derivative encoding C. muytjensii strain tol gene, pRA043, used was previously 
constructed by Zook (2012). This construct was made using a slightly more complex technique and was 
based off of the sequence for Klebsiella pneumoniae (subspecies pneumoniae, strain MGH7857, 
Genebank accession NC_009648.1). Primers were designed to amplify the homologous initial codons of 
the tolA gene between this strain and E. coli (Lazar, 2014; Zook, 2012). These initial sequence portions 
were used as little similarity existed between the sequences upstream from the tolA gene. The utilized 
bases of both K. pneumoniae and the W3110 E. coli strain were 883,749-883,763. These bases were 
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added to the three-prime end of an EcoRI site to facilitate cloning (Lazar, 2014; Zook 2012). This forward 
primer, ORA0296, created by Zook (2012) can be seen in Table III. The reverse primer was constructed 
to complement a portion of the sequence between tolA and tolB of K. pneumoniae (Lazar, 2014; Zook, 
2012). The bases 835,211-835,159 were added to the three-prime end at a KpnI site to facilitate cloning. 
This primer was designated ORA0270. PCR reactions were run using these primers and the DNA 
templates to clone the constructed mutants. The sequences of the genes of interest were confirmed with 
dideoxy sequencing (Lazar, 2014; Zook, 2012).  
Each primer was approximately 30 base pairs long that complemented the template DNA. These 
primers also contained the intended mutation to remove the glutamine (Q) from the extreme carboxy 
terminus of the C. muytjensii strain and add the glutamine to the extreme carboxy terminus of the E. coli 
of the tolA gene (Gertz, 2016). This essentially caused one strain’s mutated extreme carboxy terminus to 
appear as the C-terminus of the wild-type strain. pRA0703 and pRA0704 were the forward and reverse 
primers used to do so in E. coli, respectively, and pRA0705 and pRA0706 were used to mutate C. 
muytjensii (Gertz, 2016). The mutation to create pRA076 was executed at residue 421 (the final amino 
acid codon) to add a terminal glutamine. The deletion of the terminal glutamine to create pRA067 was 
done at residues 1267-1269 of the amino acid sequence (the final codon).  
The Y. enterocolitica primers were created through similar means, however, the focus was on a 
more upstream portion of the C-terminus. The lysine encoded by bases 895-897 differed from the alanine 
and serine found at that site in E. coli and C. muytjensii, respectively. Due to the different biochemical 
natures and behaviors of lysine and the other two amino acids, it was posited that this site could confer 
colicin N sensitivity to Y. enterocolitica if mutated to possess the alanine as E. coli does. 5’ 
phosphorylated primers ORA0732 and ORA0733 were constructed to induce this mutation through site-
directed mutagenesis.  
PCR and Mutating the tolA Gene in its C-Termini 
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Primers are designed in the lab and ordered from the Invitrogen Company. Two sterile PCR tubes 
were obtained. One tube will serve as a negative control for each respective reaction and will be labeled 
“EC (-)” or “CM (-)” and will designate their mutation as appropriate. The experimental tube was labeled 
“EC (+)” or “CM (+)” and designated the mutation appropriately. The experimental tube reactions 
consisted of 35 μL of deionized water, 1 microliter of the appropriate plasmid (pORA004, pORA028, 
pORA043), 10 μL of 10x Reaction Buffer, 1 μL of each appropriate forward and reverse primer 1μl of 
deoxynucleotides/dNTP’s, and 1μL of Taq DNA polymerase. The negative control tubes will contain 
each of these contents, but with an extra 1 μL of deionized water and the omission of any plasmid to use 
as template DNA. One tube contained 2 μL of MgCl2 and another contained 1 μL MgCl2 to replace the 
same volume of water and facilitated PCR better. The tubes will be run on a previously constructed PCR 
setting in the thermocycler called “KGXL”. These samples will be stored in the freezer. Each PCR was 
run for a total of 35 cycles, with denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds, 
and extension at 68°C for 6 minutes through the first 34 cycles, and 12 minutes for the final.  
Gel Electrophoresis 
A sample of the PCR product was resolved on a 1% agarose gel at 110v with a 1 kb ladder side 
standard, to confirm the product contained an amplification of the entire plasmid. A 1% agarose gel was 
made using 0.5x Tris-EDTA buffer. Approximately 0.8 gram of agarose was measured out and mixed 
with 80 mL of 0.5x Tris-EDTA buffer. The mixture was weighed, then heated at 30 second intervals in 
the microwave until the solution appeared clear and the agarose was fully dissolved. The mixture was 
weighed between intervals and any lost mass was replaced by the addition of deionized water. The sample 
was equilibrated to ~50 C for 10 minutes. 4 μL of ethidium bromide was added to the agarose. This 
mixture was poured into an assembled gel box and allowed to harden for 15-20 minutes. Sterile 
Eppendorf tubes were appropriately labeled for each sample being run on the gel. 5 μL of deionized water 
and 3 μL of loading dye were added to each tube. 5 μL of the appropriate purified PCR sample was added 
to the corresponding tube. Each sample mixture was injected into its own well within the gel. The anode 
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of the electric power supply was attached to the electrode closest to the wells and the cathode to the 
farthest electrode from the wells. The voltage was set at 110V and the gel was run for approximately 1 
hour. DNA movement was observed by placing the gel above ultraviolet light. Protective eye-ware is 
worn during viewing. Samples that moved farthest from the anode were smaller than those that traveled 
less distance. 
Qiagen Purification 
All samples were purified using this kit. Sterile columns were obtained and appropriately labeled 
for both the negative control and experimental tube. 250 μL of the provided PB buffer was added to the 
PCR sample. The mixture was placed in its respective column, which was then placed in its respective 
collection tube. The sample was centrifuged at 14,000 revolutions per minute (rpm) for 1 minute. The 
flow through was discarded. 750 μL of the PE buffer was added to each sample’s column. The tubes were 
centrifuged again at the same speed for the same time period. The flow through was discarded. The tubes 
were centrifuged at 14,000 rpm for 30 seconds. The collection tubes were discarded. The columns were 
placed in sterile, appropriately labeled Eppendorf tubes. 30-50 μL of 10 mM Tris elution buffer was 
added to each sample. The sample was allowed to rest for 2 minutes. The samples were then centrifuged 
at 14,000 rpm for one minutes. The column was discarded and the final purified sample remained in the 
Eppendorf tube. These samples were stored in the freezer.  
DpnI Site Digestion and Ligation 
The PCR product was digested with the DpnI restriction enzyme to remove methylated DNA and the 
initial template DNA from pRA004, pRA028, and pRA043. 2 μL of each sample’s purified PCR product 
was added to its own sterile Eppendorf tube. 2 μL of Buffer #4 was added to each tube along with 14 μL 
of deionized water, 1 μL of the DpnI enzyme. The mixtures were incubated 37 C for one hour.  
The purified, digested PCR product were ligated to re-circularize the products into a plasmid. To 
perform the ligation, tubes were prepared and appropriately labeled for each species. 8 μL of dionized 
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water, 10 μL of Quick Ligase Buffer, 1 μL of the appropriate digested DNA, and 1 μL of Quick ligase 
were added to each tube. Negative controls were made for each of these tubes. They lack DNA but 
compensate with an additional microliter of water. All tubes were incubated at room temperature for 30 
minutes. 
Transformation of Each Plasmid into Competent 2987α Cells 
Once cells were ligated, the circularized products were transformed into DH5- chemically 
competent E. coli cells from New England Biolabs per product protocol (Lazar, 2014). 20 μL of frozen 
C2987α cells were deposited in sterile Eppendorf tubes. They were labeled appropriately for each strain 
that will be transformed (oRA 004, 028, and 043). 2 μL of the digested/ligated DNA from above were 
added to each tube as appropriate. The tubes were incubated on ice for 30 minutes, then heat shocked for 
two minutes at 37 C. The tubes were put back on ice for two minutes and mixed with 500 μL of LB. 
They were then incubated at 37 C for one hour. 100 μL of each was plated on its own LB-Amp plated at 
incubated overnight at 37 C. Growth was evaluated and selection for transformants on each plate was 
conducted the following day.  
Alkaline Lysis for Plasmid Purification 
Overnight cultures of each plasmid strain in the 2987α cells were made and appropriately labeled. 
The media used will be LB-Amp (2 mL). The samples were incubated at 37 C. Then, 1.5 mL of each 
oFvernight culture was placed in its appropriate sterile Eppendorf tube and labeled. The tubes were 
centrifuged for 5 minutes at 14,000 rpm. The supernatant was aspirated off of each sample. The pellet was 
mixed and resuspended in 100 μL of Solution I (11.7 mL of 20% 50mM glucose, 2.5 mL of 1.0 M Tris 
(pH 8.0), 2.0 mL of 0.5 M DTA (pH 8.0), and 84 mL of deionized water). 200 μL of Solution II was 
added (8.8 mL of deionized water, 200 μL of 10N NaOH, and 1.0 ml of 10% SDS). The solution was 
gently mixed, then stored on ice for 5 minutes. 150 μL of Solution III (50 ml of 5M potassium acetate, 
11.5 mL acetic acid, and 28.4 mL deionized water) was then added to each tube and mixed.  
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The tubes were incubated on ice for 5 minutes, then centrifuged for 5 minutes at 14,000 rpm. The 
supernatant was poured into fresh, appropriately labeled tubes. 200 μl of buffer-saturated phenol and 200 
μL of 1:24 chloroform:isoamyl alcohol was added to each tube, then mixed with a Vortex. The tubes were 
centrifuged for 2 minutes at 14,000 rpm. The top layer was collected and deposited into a new, sterile, and 
appropriately labeled tube. 1 ml of 100% ethanol was added to each tube and mixed. The mixture rested 
at room temperature for 2 minutes. The tubes were then centrifuged for 5 minutes at 14,000 rpm and the 
supernatant was aspirated afterwards. Each tube was rinsed with 1 ml of 70% ethanol, spun for 1 minute 
at 14,000 rpm, and the ethanol was removed. The tubes were air dried for 30 minutes. The pellet was 
resuspended in 20-50 μL of deionized water and stored in the freezer 
Transformation into 1038 TolA- Cells 
 The plasmids from overnight cultures were transformed into the ΔtolA strain RA1038 using the 
protocol demonstrated by Chung et al. (1989). Overnight cultures were made in 5 mL of LB broth culture 
of the 1038 cells. These cells were diluted 1:100 by placing 50 μL of the overnight cultures in 5 mL of LB 
broth. One test tube was allotted for each plasmid (pRA004, pRA028, pRA043) respectively. These 
cultures were incubated at 37 C and shaken until their absorbance measurement reads 0.5 on the 
spectrometer. These cultures were divided as 1 mL aliquots in Eppendorf tubes and chilled on ice for 5 
minutes. The tubes were be spun for ten minutes at 14,000 rpm. The supernatant was removed with a 
pipet tip/aspiration system. The pellet was suspended in chilled 1X TSS buffer (containing 1.0g of 
Tryptone, 0.5g of yeast extract, 1.0g of NaCl, 10g of polyethylene glycol, 4 mL of DMSO, 100 mL 
deionized water, and 5 ml of MgSO4. The solution had a 6.21 pH. It was filtered using a 0.45 micrometer 
syringe filter). 1 μL of the appropriate plasmid was placed in the correct tube and incubated on ice for half 
an hour. The tubes were then heat shocked for two minutes at 37 C. 500 μL of LB broth was added. The 
tubes were incubated at 37 C for one hour. 100 μL of each sample were plated on its own LB-Ampicillin 
(LB-Amp) plates. They were incubated overnight at 37 C. Negative controls were made for each sample 
in the same way, but they lacked any plasmid. Growth of the plates was evaluated to identify 1038 
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transformants. These cells were inoculated into 5 mL LB supplemented with ampicillin to prepare for spot 
titer phenotypes on T-plates.  
Genetic Sequencing 
DNA sequences of plasmids that behaved with the appropriate phenotype were ordered from the 
University of Chicago Comprehensive Cancer Center. These sequences can be found in the Appendix. 
The DNA samples of each plasmid were prepared for sequencing then sent off. Once the sequences were 
returned, they were analyzed to ensure the appropriate mutation is in each sequence. Further screening for 
mutants was done by creating overnight cultures of each strain, plating them on LB-Amp, and evaluating 
their growth.  
T-Top Plates 
Overnight cultures of the species plated above were made in 5 mL of LB-Amp. 5 μL of 100 mM 
arabinose was diluted in 5 mL of LB-Amp broth. 25 μL of each culture was deposited in 5 ml of LB-Amp 
with and without L-arabinose, respectively. Therefore, two tubes existed for each sample and only one of 
those possessed L-arabinose. Pre-made T-top solution was warmed until liquid. 50 μL of 10X ampicillin 
and 20μL Ca2+ in the form of 500 mM CaCl2 were added to 20 ml of T-top agar. 100 μL of each sample 
was mixed in a separate tube with 3 mL of T-top broth. This was poured on T-plates until evenly spread 
and cooled until polymerization. 
Colicin Sensitivity Spot Titers  
To test transformed colonies for susceptibilities to colicins A and N, spot titers were performed. 
The T-top plates made previously were used for this experiment. The plates were divided into half, with 
the top half labeled as “colicin A” and the bottom half as “colicin N”. 9 sterile Eppendorf tubes were 
obtained for each colicin and labeled a concentration from 100 to 10-8. Each colicin was respectively 
diluted 1:10 from 100 to 10-9. 1 μL of each sample was spotted onto the appropriate plate. This was done 
in such a manner that when viewed from the agarose side of the plate, the front row read 10-1 to 10-4 and 
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the bottom row read 10-5 to 10-9. These plates were incubated for 24 hours at 37 C then evaluated for 
zones of inhibition. Any zone of inhibition is indicative of a functioning Tol system and TolA protein that 
has been successfully parasitized by the colicin.  
Triplicate 
The spot titers were performed in triplicate as described above to ensure accurate and 
reproducible results. Images of these results were captured and can be seen below. 
 
Results 
 The spot titer results of pRA067 and pRA077 are illustrated below in Figures 2 and 3 for colicins 
A and N respectively. Images captured of this experiment’s plates can be seen in Figure 4. These results 
are also tabulated in Table IV. The pRA004 (E. coli wild-type) positive control experienced sensitivity to 
both colicins A and N through the 5-9 dilution. The pRA043 (C. muytjensii wild-type) experienced 
sensitivity to colicin A to the same degree, but only experienced sensitivity to colicin N through the 5-4 
dilution. The mutants behaved in such a way that mimicked the sensitivity of the wild-type species its 
mutated extreme C-terminus was constructed to mirror. The mutated E. coli strain (pRA076) that was 
designed to possess a terminal glutamine (Q) and appear as the extreme C-terminus of C. muytjensii 
experienced the same degree of sensitivity to colicin A as the previously mentioned strains. However, it 
exhibited less sensitivity to colicin N than wild-type E. coli (pRA004) and its sensitivity to colicin 
mirrored that of wild-type C. muytjensii (pRA043). The mutated C. muytjensii strain (pRA067) that had 
its extreme C-terminus Q deleted to appear as the extreme C-terminus of wild-type E. coli exhibited 
sensitivity to colicin A through 5-9 like all other strains. However, a greater degree of sensitivity to colicin 
N was observed when compared to wild-type C. muytjensii.  
 Figure 5 displays the spot titer results obtained from pRA077 in 1038 tolA cells. Sensitivity to 
colicin A extended from 5-1 to 5-9 dilutions. However, sensitivity to colicin N only extended from 5-1 to 5-4 
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dilutions as was characteristic of the wild-type strain, pRA028 (Gertz, 2016). This suggest that the 
binding domain mutated may not prove significant to domain III of TolA binding to colicin N.  
Conclusion 
Overall, the expected results were successfully obtained from project for E. coli and C. mutjensii. 
By mutating the glutamine in the extreme carboxy-terminus of the TolA protein in E. coli and C. 
muytjensii, colicin N sensitivities were altered. By switching the extreme carboxy termini of the two 
species where the glutamine through the presence or absence of a glutamine, the sensitivity of colicin N 
was altered. The results obtained support the belief that the presence of a terminal glutamine on the 
extreme carboxy terminus of the TolA protein substantially alters the translocation across the cell 
envelope and the import of colicin N in E. coli and C. muytjensii. The results obtained suggested the 
extreme C-termini of these species prove crucial in facilitating group A colicin translocation, most 
notably of colicins A and N for these two species. Additionally, this project has identified this TolA 
region as a necessary binding site for colicin N translocation, and potentially other Group A colicins. 
However, results were less favorable for pRA077. Although this mutant possessed the intended mutation, 
it exhibited similar colicin N sensitivity to the wildtype pRA028. This suggests that this exact region is 
not crucial for colicin N binding to domain III of TolA. Future experimentation in which the extreme-
terminal glutamine of this strain is removed may affect colicin N sensitivity as seen in the previous 
strains.  
Future experimental prospects consist of testing colicin A and N sensitivities of species with 
various degrees of genetic similarity to the TolA of the species in this project. Mutations can be made in 
these species to determine if any other regions of TolA alter colicin N import into these species. One such 
intended project is introducing the same mutation induced in pRA077 in a previously constructed Y. 
enterocolitica that lacked a terminal glutamine (Gertz, 2016). This new strain would possess two 
mutations such that the extreme C-terminus sequence would be identical to E. coli and the upstream 
mutation would possess an alanine as E. coli does. Mutating Y. enterocolitica to possess a sequence more 
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similar to E. coli is desirable as wild-type E. coli proves more sensitive to colicin N than wild-type C. 
muytjensii.  
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Appendix 
 
Figure 1. The TonB and Tol protein systems (adapted from Lazar, 2014). ExbB, ExbD, and TonB of the 
TonB system appear to be analogous to TolQ, TolR, and TolA proteins of the Tol system, respectively. 
These proteins interact with Lpp and OmpA in the TonB system whereas the Tol system requires these in 
addition to TolB and Pal. The TonB system aids in transporting iron and vitamin B12 while the Tol system 
supports OM integrity. Both systems can be used by phage or colicins to enter the cell. Both require outer 
membrane proteins like FepA and OmpF to facilitate such translocations. 
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Figure 2. Colicin A sensitivities experienced by each sample. Colicin A is used as a positive control as all 
samples demonstrate equivalent sensitivity.  
 
Figure 3. Colicin N sensitivities experienced by each sample. Samples with an E. coli-like C-terminus 
experienced more sensitivity than those with a C. muytjensii-like C-terminus. 
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Figure 4. The spot titer plate results observed of pRA067 and pRA076 plasmids in 1038 tolA cells. 
pRA004 and pRA076 can be seen in the first row from left to right. The second row consists of pRA043 
and pRA067 from left to right. The final plate consists of pBAD24 to function as a negative control. The 
top half of the plate contains the colicin A spot titers and the bottom half of the plate contains the colicin 
N spot titers.  
Figure 5. The spot titer plate results observed of pRA077 in 1038 tolA cells. pRA077 behaved similarly 
to wild-type Y. eneterocolitica in regard to colicin N sensitivity although the mutation was present. c 
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E.coli (pRA004) KNNGASGADINNYAGQIKSAIESKFYDASSYAGKTCTLRIKLAPDGM 
Y. ent (pRA028) KKSGASAGDISGYLGQLTAAIQSKFYDADLYKGRTCNLRIKLAPDGL 
C. muy (pRA03) KNNGASGAEINGYASQIKAAIESKFYDASSYSGKTCTLRIKLAPDGL 
 
E.coli LLDIKPEGGDPALCQAALAAAKLALIPKPPSQAVYEVFKNAPLDFKP- 
Y. ent LIDVKQEGGDPALCQAAIAAAKLAKIPKPPSQDVYEVFKNAPLVFKPQ 
C. muy LLDIQSEGGDPALCQAAISAARQAKIPKPPSQAVYEVFKNAPLLFKPQ 
 
Figure 6. Comparison of the domain III amino acid sequences of TolA protein of the three wild-type 
strains used in this study. Bolded letters indicate where mutations were made as described previously. 
 
Table I. List of Group A colicins and their receptors, translocation mechanisms and cytotoxicity. Adapted 
from Cascales et al. (2007) and Lazar (2014). 
Colicin Primary 
receptor (OM) 
Translocater/ 
Secondary 
Receptor 
Mechanism of 
Translocation 
Cytotoxicity  
A BtuB OmpF TolA,B,Q,R Pore-forming 
N LPS OmpF TolA,Q,R Pore-forming 
 
Table II. Summary of bacterial strains used. Adapted from Lazar (2014) 
Strain Relevant genotype/phenotype Source/Reference 
W3110 Wild type E. coli Hill and Harnish, 1981 
NEB5-α Chemically competent E. coli New England Biolabs 
RA1038 W3110 (ΔtolA) Weitzel and Larsen, 2008 
ATCC51329 Cronobacter muytjensii American Type Culture Collection 
ATCC23715  Y. enterocolitica American Type Culture Collection 
BZB2101 Carries a low-copy plasmid that 
encodes colicin A 
Anthony Pugsley, Institut Pasteur 
BZB2123 Carries a low-copy plasmid that 
encodes colicin N 
Anthony Pugsley, Institut Pasteur 
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Table III. Summary of plasmids used. 
Plasmid Releveant 
Genotype/Phenotype 
Source or Reference 
pBAD24 araBAD promoter, AraC, ampr Guzman et al., 1995 
pRA004 pBAD24 encoding E. coli 
TolA 
Weitzel and Larsen, 2008 
 
pRA028 pBAD24 encoding Y. 
enterocolitica TolA 
Weitzel and Larsen, 2008 
pRA043 pBAD24 encoding C. 
muytjensii TolA 
Zook, 2012 
pRA067 pBAD24 encoding C. 
muytjensii TolA with 
mutations 
Gertz, 2016  
pRA076 pBAD24 encoding E. coli 
TolA with mutations 
Present Study 
pRA077 pBAD24 encoding E. coli 
TolA with mutations 
Present Study 
 
 
Table III. Primers constructed and utilized in this project 
Primer # Description Sequence 
Amplificat
ion 
primers 
Bacterial Species Primer Sequence 
ORA0269 Klebsiella pneumoniae 
(MGH78578, 
NC_009648.1) bases 
883749-883763 
5’-CCGAATTCACGATGTCAAAGGCAACCG 
ORA0270 Klebsiella pneumoniae 
(MGH78578, 
NC_009648.1) bases 
835211-883763 
5’-GCTGGTACCCTACTACTCGTAATGCCTGC 
Mutationa
l primers 
  
ORA0703 E. coli tolA forward,  
mutagenic 
5’-
GGCAGTATACGAAGTGTTCAAAAACGCGCCATTGCTG
TTTAAACCGCAGTAATCTAGAGTCGACCTGCAGGC 
ORA0704 E. coli tolA reverse,  
mutagenic 
5’-
GGCGCGTTTTTGAACACTTCGTATACTGCCTGGTATAC
TGCCTGGCTTGGTGGTTTCGGGATCTTCGCAAGTTTAG
CTGCTGCC 
ORA0705 C. muytjensii forward, 
mutagenic 
5’-
GGCTGTATACGAAGTCTTTAAAAACGCATTGGATTTT
AAACCGTGATTACCGGTAACAAAACCGCC 
ORA0706 C. muytjensii reverse, 
mutagenic 
5-
CGCGTTTTTAAAGACTTCGTATACAGCCTGGCTTGGC
GGTTTAGGAATCTTAGCCTGTCGGGCGGCGG 
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ORA0732 Y. enterocolitica 
forward, mutagenic 
5’-P-CCGCACCTGTAATCTGC 
ORA0733 Y. enterocolitica 
reverse, mutagenic 
5-P-CCGGCGTAAAGATCAGC 
 
Table IV. Sensitivity to group A colicins. Scores in the table indicate the highest fivefold dilution of the 
indicated colicin resulting in zones of inhibition. A score of 9 would indicate that the cells are sensitive 
the given colicin through the 5-8 dilution. 
TolA phenotype  Colicin A  Colicin N  
TolA  0 0  
E. coli (pRA004) 9 9 
C. muytjensii (pRA043)  9  4 
E. coliQ (pRA076) 9 4 
C. muytjensiiQ (pRA067) 9 9 
Y. enterocolitica (pRA028) 9 4 
Y. enterocolitica (pRA077) 9 4 
 
TolA Amino Acid Sequences of Wild-Type Species 
Escherichia coli 
Domain I: 
1- MSKATEQNDKLKRAIIISAVLHVILFAALIWSSFDENIEASAGGGGG -47 
Domain II: 
48- SSIDAVMVDSGAVVEQYKRMQSQESSAKRSDEQRKMKEQQAAEELREKQAAEQ 
ERLKQLEKERLAAQEQKKQAEEAAKQAELKQKQAEEAAAKAAADAKAKAEADAKAA 
EEAAKKAAADAKKKAEAEAAKAAAEAQKKAEAAAAALKKKAEAAEAAAAEARKKA 
ATEAAEKAKAEAEKKAAAEKAAADKKAAAEKAAADKKAAEKAAAEKAAADKKAAA 
EKAAADKKAAAAKAAAEKAAAAKAAAEADDIFGELSSGKNAPKT -310 
Domain III: 
311-GGGAKGNNASPAGSGNTKNNGASGADINNYAGQIKSAIESKFYDASSYAGKTCTLR 
IKLAPDGMLLDIKPEGGDPALCQAALAAAKLAKIPKPPSQAVYEVFKNAPLDFKP-421 
Chronobacter muytjensii  
MAKATEQNDKLKRAIIISVVLHLLLIALLIWSSFDEHINEDAAGGGGGSAIDAVMVDPGAVVQQY
NRQQQQQASAKQAAEQREKQAQQQAEELREKQAAEQE            
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RLKKLEQERLEAQEKAQQQAEQQKQAEEAAKRAQEQQKQAEEAAAKAAADAKAKADAQ              
AKAAEEAAKKAAADAQKKAQEEAAKAAAAAKKAQEEAEKKAAADAAKKAQQDAEKKAA                  
AEAAKKAAAEKAAAEKAAAAEKAAAEKKAAAAKAAAEKAAAEKAAADKKAAAEKAAAKKA
AAAKAAAEKAAAAEGVDDLLGDLSSGKNAPKTGGGAKGSNAAPAGSGNSKNNGASGAEINGY
ASQIKAAIESKFYDASSYSGKTCTLRIKLAPDGLLLDIQSEGGDPALCQAAISAARQAKIPKPPSQA
VYEVFKNAPLLFKPQ 
Yersinia enterocolitica (Based off Yersinia pestis; Lazar, 2014; Zook, 2012). 
MWKSSVGKATEQNDKLNRAVIVSVVLHIILIALLIWGSLTQTTE         
MGGGGAGGEVIDAVMVDPGAVTEQYNRQQQQQTDAKRAEQQRQKKAEQQAEELQQKQA                    
AEQQRLKELEKERLQAQEDARQAAEEQKKQAAEQQKQAAEQQKAAAAAAAKAKEEQKQ                    
AEAAAAQAKAEADKLVKAQAEAQKKAEAEAKKEAAVAAAAKKQAEADAKKAAADAKKAAA
AEAKKKAAAEAAAATDVDDLFGGLANSKNAPKSGSGAGAAAAGKGGGKKSGASAGDISGYLG
QVTAAIQSKFYDADLYKGRTCNLRIKLAPDGLLIDVKQEGGDPALCQAAIAAAKLAKIPKPPSQD
VYEVFKNAPLVFKPQ 
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